Mobocertinib (TAK-788)

EGFR exon 20 mutant inhibitor, oral once-daily

Breakthrough Therapy for ex20+ NSCLC (Ph. I)

from cellular screening + SBDD

Cancer Discovery, Feb. 25, 2021

ARIAD/Takeda, Cambridge, MA

4. The ARIAD/Takeda EGFR exon 20 insertion mutant (EGFRex20ins) inhibitor TAK-788 is a Breakthrough Therapy for patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor EGFR exon…

become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

Stay up-to-date and save more time with exclusive members-only content
On-board new team members with educational content and case studies

Generate ideas and discussion with easy-to-read slide decks
Generate ideas and discussion with easy-to-read slide decks